Plant Name: Foeniculum vulgare
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; ADRA2C; ADRA2A; GPBAR1; HCAR2; | |
| TSHR; NMUR2; | |
| ALPI; PLA2G1B; TDP1; BLM; FAAH; RECQL; CTDSP1; TERT; PKM; HPGD; HSD17B1; AKR1B1; HSD17B10; IDO1; ALOX15; ALDH1A1; HSD17B2; AKR1B10; NOX4; BRCA1; APEX1; POLB; | |
| PTPN1; CDC25B; PTPN2; | |
| ACHE; GAA; | |
| TRPA1; | |
| CDK8; DAPK1; FLT3; CDK9; MAPK1; | |
| CA3; CA14; CA5B; CA6; CA1; CA9; CA7; CA4; CA2; CA12; CA5A; | |
| AR; | |
| NR1H4; | |
| ESRRA; | |
| PPARA; PPARG; PPARD; | |
| KDM4E; | |
| ALOX5; PTGS1; TYR; XDH; | |
| CASP7; CASP1; | |
| MMP1; | |
| TLR2; | |
| AHR; HIF1A; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MCL1; MAPT; FABP3; RAB9A; NPC1; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.817E-12 | 2.519E-09 | ALPI, AR, BLM, BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, L3MBTL1, MMP1, NR1H4, PPARA, PPARD, PPARG, PTPN1, TP53 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.692E-11 | 1.466E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, IDO1, NOX4, PTGS1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.956E-11 | 1.958E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.027E-10 | 1.244E-07 | ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.415E-10 | 2.144E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.738E-10 | 2.231E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.790E-09 | 6.388E-07 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.474E-09 | 1.146E-06 | AHR, AR, ESRRA, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.497E-09 | 2.163E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.292E-08 | 1.637E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.196E-07 | 2.578E-05 | APEX1, AR, BLM, BRCA1, CASP7, CYP1A1, CYP1B1, FLT3, MAPK1, NOX4, NPC1, PPARG |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.572E-07 | 7.007E-05 | ABCC1, ALOX15, ALOX5, PLA2G1B, TLR2 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 3.882E-07 | 7.481E-05 | AR, ESRRA, NR1H4, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.307E-07 | 8.085E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 5.112E-07 | 9.355E-05 | AHR, AKR1B1, APEX1, CA3, CYP1A1, CYP1B1, HPGD, MAPK1, POLB, TLR2, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.043E-06 | 1.774E-04 | AR, CDK8, CDK9, ESRRA, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.370E-06 | 2.211E-04 | CYP19A1, FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.045E-06 | 3.009E-04 | AHR, AR, BRCA1, ESRRA, NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 2.138E-06 | 3.125E-04 | ALOX15, ALOX5, HPGD |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 2.300E-06 | 3.294E-04 | AHR, CDK9, PPARA, TERT |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.830E-06 | 3.951E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 2.964E-06 | 4.111E-04 | CASP1, FABP4, HIF1A, IDO1, PLA2G1B, TLR2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.115E-06 | 4.278E-04 | AR, BRCA1, ESRRA, NR1H4, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.650E-06 | 4.759E-04 | AR, CYP3A4, ESRRA, HSD17B1, NPC1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.895E-06 | 7.171E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 8.888E-06 | 1.024E-03 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.040E-05 | 1.169E-03 | AR, BRCA1, DAPK1, LMNA, MCL1, TERT |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.174E-05 | 1.285E-03 | ADRA2A, FFAR1, HIF1A, NOX4, NR1H4, PPARG, PTPN2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.345E-05 | 1.457E-03 | CA2, CA7, HCAR2, HIF1A, MAPK1, NPC1, NR1H4, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.365E-05 | 1.471E-03 | AKR1B1, CYP19A1, CYP1A2, IDO1, NOX4, XDH |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 1.771E-05 | 1.836E-03 | APEX1, BLM, BRCA1, POLB, TP53 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.023E-05 | 2.021E-03 | AHR, AKR1B1, ALOX5, APEX1, AR, BLM, BRCA1, CASP7, CDC25B, CDK8, CDK9, CTDSP1, ESRRA, FABP5, HIF1A, HPGD, L3MBTL1, LMNA, MAPK1, MCL1, NR1H4, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, SMN1, SMN2, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0097305; response to alcohol | 2.107E-05 | 2.095E-03 | BLM, BRCA1, CA3, HPGD, POLB, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.293E-05 | 2.259E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.303E-05 | 2.259E-03 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 2.666E-05 | 2.557E-03 | ADRA2A, ADRA2C, AHR, HIF1A, MCL1, PPARD, PPARG, TLR2, TP53, TTR, TYR |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 2.945E-05 | 2.800E-03 | ALOX15, ALOX5, PLA2G1B, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.984E-05 | 2.825E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 3.174E-05 | 2.979E-03 | AR, CYP1B1, FABP3, IDO1, LMNA, NOX4, PPARD, PPARG, PTPN2, TERT, TLR2, TP53, XDH |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.232E-05 | 3.021E-03 | ABCC1, ADRA2A, CA2, CA4, CA9, HPGD, TSHR |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 3.435E-05 | 3.170E-03 | ADRA2A, ADRA2C, ALOX15, AR, FFAR4, FLT3, MAPK1, NOX4, PLA2G1B, PTPN1, XDH |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 3.581E-05 | 3.276E-03 | AKR1B1, HPGD, PPARD, PPARG, TERT, TP53 |
| BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 4.073E-05 | 3.636E-03 | ADRA2A, ADRA2C, ALDH1A1, CASP1, CASP7, CDC25B, DAPK1, FLT3, HIF1A, MAPK1, MAPT, NMUR2, NOX4, PLA2G1B, PPARG, PTPN1, TERT, TSHR, XDH |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.197E-05 | 3.715E-03 | FABP3, FFAR1, NR1H4, PPARG, TLR2 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 4.727E-05 | 4.101E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 5.350E-05 | 4.605E-03 | ALOX15, BRCA1, CASP1, CDK9, DAPK1, FABP4, FLT3, HIF1A, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 5.683E-05 | 4.853E-03 | FABP3, PKM, PLA2G1B, PPARA, PPARG, TLR2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.782E-05 | 4.899E-03 | ALOX15, ALOX5, HPGD |
| MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 5.782E-05 | 4.899E-03 | CDK8, CDK9, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 5.898E-05 | 4.940E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.858E-05 | 5.470E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.858E-05 | 5.470E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.858E-05 | 5.470E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.858E-05 | 5.470E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.858E-05 | 5.470E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 6.996E-05 | 5.480E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 6.996E-05 | 5.480E-03 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 7.469E-05 | 5.788E-03 | APEX1, CASP1, NOX4, PPARG, TP53, TYR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 9.592E-05 | 7.177E-03 | ADRA2A, CA2, CA7, HCAR2, HIF1A, MAPK1, NPC1, NR1H4, PLA2G1B, TRPA1 |
| BP | GO:0051179; localization | GO:0015909; long-chain fatty acid transport | 1.231E-04 | 9.025E-03 | FABP3, NMUR2, PLA2G1B, PPARG |
| MF | Unclassified; | GO:0004872; receptor activity | 1.309E-04 | 9.567E-03 | ADRA2A, ADRA2C, AHR, AR, ESRRA, FFAR1, FFAR4, FLT3, GPBAR1, HCAR2, HPGD, NMUR2, NPC1, NR1H4, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.324E-04 | 9.614E-03 | AKR1B1, CYP19A1, CYP1A2, IDO1, NOX4, XDH |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 1.325E-04 | 9.614E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.367E-04 | 9.636E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.367E-04 | 9.636E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.367E-04 | 9.636E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.367E-04 | 9.636E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.367E-04 | 9.636E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.367E-04 | 9.636E-03 | ALDH1A1, AR |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.416E-04 | 9.948E-03 | MAPK1, MAPT, PPARA, PPARG, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.348E-23 | 2.557E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.178E-16 | 2.850E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.331E-16 | 1.563E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.442E-22 | 2.436E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.640E-09 | 3.131E-07 | PLA2G1B; GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; PTGS1; CYP2C9; CYP2A6; PKM; AKR1B10; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPI; XDH; IDO1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.066E-09 | 9.008E-08 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.741E-09 | 2.107E-07 | CYP2C9; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.264E-09 | 3.131E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.157E-07 | 2.794E-06 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.280E-07 | 9.042E-06 | CYP2C9; PLA2G1B; ALOX5; ALOX15; CYP2C19; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.070E-07 | 2.794E-06 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.687E-07 | 1.068E-05 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.138E-06 | 1.748E-05 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.383E-05 | 1.947E-04 | CYP2C9; ALOX5; ALOX15; MAPK1; CYP2C19; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.500E-05 | 1.950E-04 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.733E-05 | 2.092E-04 | CYP2C9; CYP2A6; CYP1A2; CYP3A4; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.665E-05 | 9.608E-04 | AR; FLT3; MMP1; DAPK1; MAPK1; PPARG; HIF1A; TP53; PPARD |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.522E-05 | 3.968E-04 | CYP1A2; CYP1A1; CYP1B1; IDO1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.889E-05 | 4.108E-04 | MMP1; DAPK1; MAPK1; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.727E-04 | 3.804E-03 | ABCC1; CYP1B1; MAPK1; BRCA1; TP53; CDC25B; MCL1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.962E-04 | 3.812E-03 | CASP7; LMNA; MAPK1; TP53; MCL1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.355E-04 | 2.984E-03 | CA2; NR1H4; CYP3A4; ABCG2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.532E-03 | 1.079E-02 | CDK9; HPGD; FLT3; PPARG; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.258E-04 | 2.984E-03 | MAPK1; PPARG; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.258E-03 | 1.467E-02 | FABP4; TSHR; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.375E-03 | 1.487E-02 | FLT3; MAPK1; PPARD |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.144E-03 | 1.449E-02 | CASP7; CASP1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.858E-03 | 4.427E-02 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.285E-03 | 4.516E-02 | AR; MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.278E-03 | 9.393E-03 | CYP2A6; CYP3A4; XDH |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.161E-03 | 3.008E-02 | CASP7; CASP1; MAPK1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.608E-04 | 3.049E-03 | AKR1B10; GAA; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.079E-03 | 3.008E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.668E-07 | 1.634E-05 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2; PKM; FLT3; CA9; HIF1A; MAPK1; TP53 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; ACHE; ACHE; ACHE; ADRA2C; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; TLR2; MCL1; CA1; FLT3; FLT3; CA9; ACHE; HIF1A; IDO1; MAPK1; CDC25B; TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HCAR2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; FAAH; CYP3A4 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; CYP19A1; FLT3; FLT3; CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; MMP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; HCAR2 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; TERT; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; HCAR2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; ALOX5; PTGS1; FAAH |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; TYR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; ADRA2C |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; HCAR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; PPARG; PPARG; GPBAR1; PPARD; HCAR2 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ACHE; PTGS1; ADRA2C; ADRA2A; TRPA1; FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ESRRA; ALOX5; CASP1; TYR; MMP1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; ADRA2C |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; PPARG; PPARD; PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; FFAR1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |